Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL29660482 | 1.00 | WNT3A (0.34) | WNT3ATNKS2 | |
| Phosphoric Acid SCHEMBL6630320 | 0.99 | WNT3A (0.34) | WNT3ATNKS2 | |
| SCHEMBL5880375 | 0.93 | WNT3A (0.34) | WNT3ATNKS2 | |
| Hydrochloric Acid SCHEMBL5880349 | 0.92 | WNT3A (0.34) | WNT3ATNKS2 | |
| SCHEMBL7299546 | 0.75 | WNT3A (0.34) | WNT3ATNKS2 | |
| Hydrochloric Acid SCHEMBL7304498 | 0.59 | — | — | |
| SCHEMBL7299920 | 0.59 | TNKS (0.34) | WNT3ATNKS2 | |
| SCHEMBL15663037 | 0.58 | GUCY1B2 (0.34) | — | |
| SCHEMBL7296866 | 0.57 | — | — | |
| SCHEMBL7304154 | 0.56 | BACE1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6987187-B2 | reacting a pyridinyl ketone with a halogenating agent in acetonitrile and dimethylformamide; hydrolysis, animation to get a 3-amino 4-halo pyridine; chemical intermediate; by-product inhibition | SHIONOGI & CO., LTD. (JP) | 2006-01-17 | — | — | US | claimed |
| US-20040167157-A1 | Process for preparation of amidine derivatives | SHIONOGI & CO., LTD. (JP) | 2004-08-26 | — | — | US | claimed |
| EP-1408041-A1 | PROCESS FOR PREPARATION OF AMIDINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2004-04-14 | — | — | EP | claimed |
| US-20030088102-A1 | Novel process for producing fused imidazopyridine derivatives and novel crystal form | SHIONOGI & CO., LTD. (JP) | 2003-05-08 | — | — | US | claimed |
| EP-1270578-A1 | NOVEL PROCESS FOR PRODUCING FUSED IMIDAZOPYRIDINE DERIVATIVE AND NOVEL CRYSTAL FORM | SHIONOGI & CO., LTD. (JP) | 2003-01-02 | — | — | EP | claimed |
| US-20230115839-A1 | Methods For Treating Hypersomnia | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-11529358-B2 | Treatment of conditions associated with myotonic dystrophy | EMORY UNIVERSITY (US) | 2022-12-20 | — | — | US | disclosed |
| US-10688103-B2 | Methods for treating hypersomnia | BALANCE THERAPEUTICS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-9789119-B2 | Cognitive function | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20150246054-A1 | COGNITIVE FUNCTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-09-03 | — | — | US | disclosed |
| US-8946206-B2 | Methods for improving cognitive function | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-02-03 | — | — | US | disclosed |
| US-20120157445-A1 | Cognitive Function | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-06-21 | — | — | US | disclosed |
| EP-1270578-A4 | NOVEL PROCESS FOR PRODUCING FUSED IMIDAZOPYRIDINE DERIVATIVE AND NOVEL CRYSTAL FORM | SHIONOGI & CO (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040167157-A1 | Process for preparation of amidine derivatives | SHIONOGI & CO., LTD. (JP) | 2004-08-26 | — | — | US | disclosed |
| EP-1408041-A1 | PROCESS FOR PREPARATION OF AMIDINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030088102-A1 | Novel process for producing fused imidazopyridine derivatives and novel crystal form | SHIONOGI & CO., LTD. (JP) | 2003-05-08 | — | — | US | disclosed |
| US-20030088102-A1 | Novel process for producing fused imidazopyridine derivatives and novel crystal form | SHIONOGI & CO., LTD. (JP) | 2003-05-08 | — | — | US | disclosed |
| EP-1270578-A1 | NOVEL PROCESS FOR PRODUCING FUSED IMIDAZOPYRIDINE DERIVATIVE AND NOVEL CRYSTAL FORM | SHIONOGI & CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1270578-A1 | NOVEL PROCESS FOR PRODUCING FUSED IMIDAZOPYRIDINE DERIVATIVE AND NOVEL CRYSTAL FORM | SHIONOGI & CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074821-A1 | NOVEL PROCESS FOR PRODUCING FUSED IMIDAZOPYRIDINE DERIVATIVE AND NOVEL CRYSTAL FORM | SHIONOGI & CO., LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167157-A1 | Process for preparation of amidine derivatives | NAAA, ACMSD, NIT2 | WNT3A 3465/4885TNKS2 360/4885 |
| US-20030088102-A1 | Novel process for producing fused imidazopyridine derivatives and novel crystal form | HPD, CA4, SCN4A | WNT3A 3158/4885TNKS2 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.